Erdal Can Alkoçlar

Erdal Can Alkoclar (born July 7, 1986) is a Turkish inventor, scientist and IP-based project investor.

Alkoclar is the co-founder and running president of Mas Pharmaceuticals R&D company along with Metehan Yesil. He is the sole inventor of 143 applied and 282 pending patents; 44 of them being in current PCT protection. He is the inventor of the first flavonol glycoside-based antiviral ingredient currently marketed under the brands of NOVIR and FLUVOL, and has 21 Republic of Turkey Ministry of Food, Agriculture and Livestock approved formulations. Alkoclar is the owner of the first series of pharmaceutical ingredient patents which are confirmed and approved as valid and prioritized collaterals & assurance assets by several national banks, first to be confirmed in the banking history of Turkey. Alkoclar is the rights holder and applicant of the largest amount of pharmaceutical ingredient patents as sole individual in Turkey. He holds the patents of 67 anti-carcinogenic formulations, 101 Anti-viral formulations and 23 metabolic regulator ingredients.

Alkoclar and his previous R&D teamhas found and patented more than 154 methylprotodioscin derivatives; analogues used in a wide range of therapeutic fields such as neurogenesis to myogenesis; from height increase (despite the inconsistent results obtained from the formulation regarding the oral version) to adjuvant cancer therapies. Alkoclar is the sole inventor of the facile obtaining methods of hexacoumaroyl-protobioside derivatives; compounds which possesses potent Core GLC NAC III inhibiting properties.

Alkoclar holds the brand licences of 19 PGE-1 mRNA expression modulators. Those agents are primarily used in order to treat burns, to treat sexual dysfunction both as oral and transdermal formulations.[1] MYOSTIL, a myotropic formulation widely used in Middle Eastern region with muscle strength enhancing properties has been pointed and thought as a prominent result of above-mentioned research and development processes. Several famous Turkish bodybuilders including Hakan Gumus and Gursel Yanardag have been officially detected to possess a strength increase by up to 43% and 47.7% respectively by an acute oral dosing protocol which led MYOSTIL to be banned from domestic bodybuilding and other athletic competitions due to its comperable potency to Proviron in terms of lipolysis and Trenbelone in terms of muscle gain with the absence of those two anabolic agents' side effects.

Alkoclar holds the PCT approved patents of twelve 3,7-bis(2-hydroxyethyl) bonded flavonol glycoside derivatives scientifically proven to possess more potent PDE5 and PDE4 suppressive properties than several well known pde5 inhibitors including sildenafil.[2] Alkoclar and Yesil holds the ownership of more than 100 anti-viral formulation and molecular patent applications, with an estimated value of US$3,320,000,000 (precedent bank evaluation worth is taken as the basis evaluation).

Alkoclar has an ongoing law struggle against several litigations and is in the center for a number of debates regarding Yesil&Alkoclar 's patented methods of facile manufacturing of 3,7-bis(2-hydroxyl) flavonoids and glucopyranoside derivatives which provides an "advantage of unfair competition".

Novir(™), the previously mentioned antiviral formulation was as an adjunctive treatment to Sierra Leone regarding the Ebola crisis that was under the supervision of UN health inspection commission. 10 Ebola sufferers used *Novir and were able to survive the critical first 96 hours; no participants were deceased. No significant side effect was observed during and after the treatment. This process was initiated by John Sahr Yambasu, the current Moscow ambassador of the state of Sierra Leone after contacting with YesilAlkoclar R&D officials. *Novir is still on registration phase in Turkey and 23 other countries including Kazakhstan, Bulgaria, Greece, Italy, Azerbaijan, Turkmenistan and Hungary.

Alkoclar is the rightsholder of more than 1900+ anti-viral steroidal lactone, pseudalkaloids, protoalkaloids, furostanol saponins and furostanol glycosides' patent applications. Alkoclar and Yesil are the co-owners and titled inventors of HYA4312, a silicon-based 4-layered coating with pyro-resistant and potent radio wave emissive properties. Alkoclar has an ongoing legal struggle with Biotest, a sports supplements company, related to a possible infringement of several patents belonging to Alkoclar.[3] Noricaritin, the novel name given to 3,7-bis(2-hdyroxyethyl)icaritin, the active ingredient in several patent applications owned by Alkoclar and Yesil has recently been approved by Chemical Abstract Services with the CAS number of 5240-95-9[4][5][6]

Alkoclar has won a 4th prize which is given by Turkish Patent Institute for having the 4th largest number of applied patents in 2014.[2] Alkoclar received the Scientist of the Year Award for Turkey in 2016 and 2019.

[7]

References

(1) Dell'Agli, M; Galli, GV; Dal Cero, E; et al. (September 2008). "Potent inhibition of human phosphodiesterase-5 by icariin derivatives". J. Nat. Prod. 71: 1513–7.doi:10.1021/np800049y. PMID 18778098.

(2) Zhang, X; Jin, C; Li, Y; Guan, S; Han, F; Zhang, S (2013). "Catalpol improves cholinergic function and reduces inflammatory cytokines in the senescent mice induced by D-galactose". Food Chem. Toxicol. 58: 50–5. doi:10.1016/j.fct.2013.04.006. PMID 23612000.

(3)http://www.farmapatent.com.tr/index.php?option=com_content&task=view&id=3903&Itemid=34

(4) http://www.chemfaces.com/natural/Noricaritin-CFN98528.html

(5)http://www.chemblink.com/products/5240-95-9.htm

(6)http://www.albtechnology.com/noricaritin-cas-5240-95-9.html

(7)http://www.tpe.gov.tr/TurkPatentEnstitusu/allNews/newsDetail?newsId=353